These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 39397076)

  • 1. Differential regulation of expression of the protein kinases DYRK1A and DYRK1B in cancer cells.
    Vorwerk VA; Wilms G; Babendreyer A; Becker W
    Sci Rep; 2024 Oct; 14(1):23926. PubMed ID: 39397076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma.
    Massey AJ; Benwell K; Burbridge M; Kotschy A; Walmsley DL
    J Cell Mol Med; 2021 Nov; 25(22):10650-10662. PubMed ID: 34708541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B.
    Papenfuss M; Lützow S; Wilms G; Babendreyer A; Flaßhoff M; Kunick C; Becker W
    Sci Rep; 2022 Feb; 12(1):2393. PubMed ID: 35165364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel benzothiophene derivatives as potent and narrow spectrum inhibitors of DYRK1A and DYRK1B.
    Segretti ND; Takarada JE; Ferreira MA; da Silva Santiago A; Teodoro BVM; Damião MCFCB; Godoi PH; Cunha MR; Fala AM; Ramos PZ; Ishikawa EE; Mascarello A; Serafim RAM; Azevedo H; Guimarães CRW; Couñago RM
    Bioorg Med Chem Lett; 2022 Jul; 68():128764. PubMed ID: 35504513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B.
    Yousefelahiyeh M; Xu J; Alvarado E; Yu Y; Salven D; Nissen RM
    PLoS One; 2018; 13(11):e0207779. PubMed ID: 30496304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B.
    Wilms G; Schofield K; Maddern S; Foley C; Shaw Y; Smith B; Basantes LE; Schwandt K; Babendreyer A; Chavez T; McKee N; Gokhale V; Kallabis S; Meissner F; Rokey SN; Dunckley T; Montfort WR; Becker W; Hulme C
    J Med Chem; 2024 Oct; 67(19):17259-17289. PubMed ID: 39344427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human cytomegalovirus utilises cellular dual-specificity tyrosine phosphorylation-regulated kinases during placental replication.
    Hamilton ST; Hutterer C; Egilmezer E; Steingruber M; Milbradt J; Marschall M; Rawlinson WD
    Placenta; 2018 Dec; 72-73():10-19. PubMed ID: 30501876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein quality control of DYRK family protein kinases by the Hsp90-Cdc37 molecular chaperone.
    Miyata Y; Nishida E
    Biochim Biophys Acta Mol Cell Res; 2021 Sep; 1868(10):119081. PubMed ID: 34147560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors.
    Ackeifi C; Swartz E; Kumar K; Liu H; Chalada S; Karakose E; Scott DK; Garcia-Ocaña A; Sanchez R; DeVita RJ; Stewart AF; Wang P
    JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31821176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
    Szamborska-Gbur A; Rutkowska E; Dreas A; Frid M; Vilenchik M; Milik M; Brzózka K; Król M
    J Mol Model; 2019 Jan; 25(2):41. PubMed ID: 30673861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.
    Anderson K; Chen Y; Chen Z; Dominique R; Glenn K; He Y; Janson C; Luk KC; Lukacs C; Polonskaia A; Qiao Q; Railkar A; Rossman P; Sun H; Xiang Q; Vilenchik M; Wovkulich P; Zhang X
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6610-5. PubMed ID: 24239188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis.
    Chen Y; Wang S; He Z; Sun F; Huang Y; Ni Q; Wang H; Wang Y; Cheng C
    Hum Pathol; 2017 Aug; 66():48-58. PubMed ID: 28554575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer.
    Brichkina A; Ems M; Suezov R; Singh R; Lutz V; Picard FSR; Nist A; Stiewe T; Graumann J; Daude M; Diederich WE; Finkernagel F; Chung HR; Bartsch DK; Roth K; Keber C; Denkert C; Huber M; Gress TM; Lauth M
    Gut; 2024 Sep; 73(10):1684-1701. PubMed ID: 38834297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
    Ewton DZ; Hu J; Vilenchik M; Deng X; Luk KC; Polonskaia A; Hoffman AF; Zipf K; Boylan JF; Friedman EA
    Mol Cancer Ther; 2011 Nov; 10(11):2104-14. PubMed ID: 21878655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.
    Ashford AL; Dunkley TP; Cockerill M; Rowlinson RA; Baak LM; Gallo R; Balmanno K; Goodwin LM; Ward RA; Lochhead PA; Guichard S; Hudson K; Cook SJ
    Cell Mol Life Sci; 2016 Feb; 73(4):883-900. PubMed ID: 26346493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.
    Gao J; Yang X; Yin P; Hu W; Liao H; Miao Z; Pan C; Li N
    Int J Oncol; 2012 Apr; 40(4):1203-9. PubMed ID: 22159921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative splicing variants of dual specificity tyrosine phosphorylated and regulated kinase 1B exhibit distinct patterns of expression and functional properties.
    Leder S; Czajkowska H; Maenz B; De Graaf K; Barthel A; Joost HG; Becker W
    Biochem J; 2003 Jun; 372(Pt 3):881-8. PubMed ID: 12633499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma.
    Martin CE; Nguyen A; Kang MK; Kim RH; Park NH; Shin KH
    Exp Cell Res; 2021 Aug; 405(1):112656. PubMed ID: 34033760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
    Lee Walmsley D; Murray JB; Dokurno P; Massey AJ; Benwell K; Fiumana A; Foloppe N; Ray S; Smith J; Surgenor AE; Edmonds T; Demarles D; Burbridge M; Cruzalegui F; Kotschy A; Hubbard RE
    J Med Chem; 2021 Jul; 64(13):8971-8991. PubMed ID: 34143631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.
    Hu J; Deng H; Friedman EA
    Int J Cancer; 2013 May; 132(10):2258-69. PubMed ID: 23114871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.